Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Clene to release results from four Phase 2 trials in 2H, says Roth Capital » 13:33
03/29/21
03/29
13:33
03/29/21
13:33
CLNN

Clene

$13.64 /

-0.13 (-0.94%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros reiterated a Buy rating and $24 price target on Clene shares following the Q4 results. Clene reported $59M on the balance sheet by the end of December, providing a sufficient runway to support operations for the next year and half, Piros tells investors in a research note. The company expects to release topline results from four different Phase 2 clinical trials in 2H21, the analyst adds.

ShowHide Related Items >><<
CLNN Clene
$13.64 /

-0.13 (-0.94%)

CLNN Clene
$13.64 /

-0.13 (-0.94%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
CLNN Clene
$13.64 /

-0.13 (-0.94%)

Hot Stocks
Clene expects cash to fund operating expenses into mid-2022 » 07:23
03/29/21
03/29
07:23
03/29/21
07:23
CLNN

Clene

$13.83 /

-0.04 (-0.29%)

Clene's cash totaled…

Clene's cash totaled approximately $59.3 million as of December 31, 2020, compared to approximately $8.8 million as of December 31, 2019. The increase in cash during the year ended December 31, 2020 was primarily due to approximately $69.5 million net cash provided by financing activities, including $35.1 million of net proceeds from the issuance of preferred stock, $31.8 million of net proceeds from the private placement and from the reverse recapitalization, and $6.1 million of net proceeds from the issuance of convertible notes payable, offset by approximately $18.9 million of net cash used in operating activities. Clene expects that its cash as of December 31, 2020 will be sufficient to fund its operating expenses into mid-2022.

ShowHide Related Items >><<
CLNN Clene
$13.83 /

-0.04 (-0.29%)

CLNN Clene
$13.83 /

-0.04 (-0.29%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
CLNN Clene
$13.83 /

-0.04 (-0.29%)

Hot Stocks
Clene announces anticipated 2021 milestones » 07:23
03/29/21
03/29
07:23
03/29/21
07:23
CLNN

Clene

$13.83 /

-0.04 (-0.29%)

Anticipated 2021…

Anticipated 2021 Milestones: HEALEY ALS Platform Trial full enrollment: mid-2021; Phase 2 RESCUE-ALS topline data: 2H 2021; Phase 2 REPAIR-MS topline data: 2H 2021; Phase 2 REPAIR-PD topline data: 2H 2021; Phase 2 CNM-ZnAg COVID-19 topline data: 2H 2021; Initiation of Phase 2 RESCUE-PD efficacy trial: 2021.

ShowHide Related Items >><<
CLNN Clene
$13.83 /

-0.04 (-0.29%)

CLNN Clene
$13.83 /

-0.04 (-0.29%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
CLNN Clene
$13.83 /

-0.04 (-0.29%)

Earnings
Clene reports 2020 EPS ($1.10) vs. (93c) last year » 07:22
03/29/21
03/29
07:22
03/29/21
07:22
CLNN

Clene

$13.83 /

-0.04 (-0.29%)

Reports 2020 revenue…

Reports 2020 revenue $206,000 vs. $0 last year. "We are thrilled to enter this new year as a public company following the recent close of our merger and concurrent financing, which was enabled by several key milestones achieved in 2020," said Rob Etherington, president and CEO of Clene. "Over the last year, we continued advancing our clinical Phase 2 studies and Phase 3 study of CNM-Au8, a novel bioenergetic nanocatalyst, in ALS, multiple sclerosis, and Parkinson's disease and are very pleased to have reported promising preliminary clinical results that support its neuroprotective and remyelinating properties. CNM-Au8's potential as a neuroprotective and neuro-reparative nanocatalyst is further validated by its selection as one of the first three therapies to be evaluated in the Phase 3 HEALEY ALS Platform trial, the first-ever platform trial for ALS. We are thankful to our patients, their care-givers, the MGH Healey ALS Center, the Northeast ALS Consortium clinical sites, and the entire Clene team, whose dedication throughout the pandemic drove this sustained progress. Looking ahead, we are well-positioned to continue the momentum of our clinical programs. In 2021 we expect to report topline safety and efficacy data from our Phase 2 RESCUE-ALS trial, complete enrollment in the registrational HEALEY ALS Platform trial, and report topline data from our Phase 2 brain target engagement studies in MS and PD. We are grateful for the continued support of our investors, which has enabled Clene to fund these robust R&D efforts. It is with great energy and dedication that Clene will continue working towards its mission of developing bioenergetic nanocatalysts as a new class of drugs to treat significant unmet medical needs in neurodegenerative diseases while driving further value for its stakeholders."

ShowHide Related Items >><<
CLNN Clene
$13.83 /

-0.04 (-0.29%)

CLNN Clene
$13.83 /

-0.04 (-0.29%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Over a month ago
Conference/Events
Clene management to meet virtually with Benchmark » 11:25
03/19/21
03/19
11:25
03/19/21
11:25
CLNN

Clene

$13.97 /

-0.24 (-1.69%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a large group meeting with President & CEO Etherington and CFO Jeong on March 19 at 12 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$13.97 /

-0.24 (-1.69%)

CLNN Clene
$13.97 /

-0.24 (-1.69%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Conference/Events
Clene management to meet virtually with Benchmark » 04:55
03/19/21
03/19
04:55
03/19/21
04:55
CLNN

Clene

$14.21 /

+0.83 (+6.20%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a large group meeting with President & CEO Etherington and CFO Jeong on March 19 at 12 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$14.21 /

+0.83 (+6.20%)

CLNN Clene
$14.21 /

+0.83 (+6.20%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Conference/Events
Clene management to meet virtually with Benchmark » 12:25
03/17/21
03/17
12:25
03/17/21
12:25
CLNN

Clene

$14.00 /

+0.65 (+4.87%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a small group meeting with President & CEO Etherington and CFO Jeong on March 17 at 1 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$14.00 /

+0.65 (+4.87%)

CLNN Clene
$14.00 /

+0.65 (+4.87%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Conference/Events
Clene management to meet virtually with Benchmark » 12:25
03/17/21
03/17
12:25
03/17/21
12:25
CLNN

Clene

$14.00 /

+0.65 (+4.87%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a small group meeting with President & CEO Etherington and CFO Jeong on March 17 at 1 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$14.00 /

+0.65 (+4.87%)

CLNN Clene
$14.00 /

+0.65 (+4.87%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Conference/Events
Clene management to meet virtually with Benchmark » 04:55
03/17/21
03/17
04:55
03/17/21
04:55
CLNN

Clene

$13.30 /

-0.86 (-6.07%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a small group meeting with President & CEO Etherington and CFO Jeong on March 17 at 1 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$13.30 /

-0.86 (-6.07%)

CLNN Clene
$13.30 /

-0.86 (-6.07%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Conference/Events
Clene management to meet virtually with Benchmark » 04:55
03/17/21
03/17
04:55
03/17/21
04:55
CLNN

Clene

$13.30 /

-0.86 (-6.07%)

Healthcare Analyst…

Healthcare Analyst Jackson holds a small group meeting with President & CEO Etherington and CFO Jeong on March 17 at 1 pm hosted by Benchmark.

ShowHide Related Items >><<
CLNN Clene
$13.30 /

-0.86 (-6.07%)

CLNN Clene
$13.30 /

-0.86 (-6.07%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.